AADI vs. NKTX, OGI, GLSI, FTLF, EDIT, THTX, LYEL, TARA, CGEN, and SLS
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Nkarta (NKTX), Organigram (OGI), Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Editas Medicine (EDIT), Theratechnologies (THTX), Lyell Immunopharma (LYEL), Protara Therapeutics (TARA), Compugen (CGEN), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs.
Aadi Bioscience (NASDAQ:AADI) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
In the previous week, Nkarta had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Nkarta and 0 mentions for Aadi Bioscience. Nkarta's average media sentiment score of 1.78 beat Aadi Bioscience's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media.
Aadi Bioscience has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Nkarta received 53 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 78.05% of users gave Nkarta an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 8.7% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Nkarta has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Nkarta's return on equity of -27.13% beat Aadi Bioscience's return on equity.
Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.
Aadi Bioscience currently has a consensus target price of $1.67, suggesting a potential upside of 12.61%. Nkarta has a consensus target price of $14.86, suggesting a potential upside of 600.81%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Aadi Bioscience.
Summary
Nkarta beats Aadi Bioscience on 14 of the 18 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy AADI Stock Free AADI Stock Alerts